Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Alnylam Pharmaceuticals News

    134,45 € 0,00% +0,00 €
    08:00:57 Uhr Gettex aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0CBCK
    ISIN: US02043Q1076
    US-Symbol: ALNY
    Typ: Aktie
    Werbung
    Weiter aufwärts?
    Long Hebel 5,90
    ME0WM0

    Alnylam Pharmaceuticals News

    11.03.24 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire
    03.03.24 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire
    03.11.23 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire
    25.10.23 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire
    17.10.23 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire
    27.03.23 - Der Aktionär
    Übernahmekandidaten: Große Kauflaune
    09.03.23 - PR Newswire
    Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
    Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-​Regional Partnership to Commercialize RNAi Therapeutics PR Newswire
    09.03.23 - PR Newswire
    Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
    Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-​Regional Partnership to Commercialize RNAi Therapeutics PR Newswire
    15.09.22 - PR Newswire
    Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
    Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers PR Newswire
    15.08.22 - Der Aktionär
    Alnylam: Daten begeistern
    03.08.22 - Der Aktionär TV
    Opening Bell: Alnylam, Moderna, AMD, PayPal, Match Group, Ferrari
    Der Dow Jones ging gestern rund 1,2 Prozent schwächer aus dem Handel. Auch die Technologiewerte verzeichneten Verluste, allerdings deutlich geringere. Der Taiwan-​Konflikt ...
    03.08.22 - Der Aktionär
    Kursexplosion von 55 Prozent: AKTIONÄR‑Tipp startet nach Studiendaten durch
    03.08.22 - PR Newswire
    Thinking about trading options or stock in Apple, Alnylam Pharmaceuticals, Atlas Air Worldwide, Alteryx, or Chevron?
    Thinking about trading options or stock in Apple, Alnylam Pharmaceuticals, Atlas Air Worldwide, Alteryx, or Chevron? PR Newswire
    13.07.22 - Der Aktionär
    Alnylam verklagt Pfizer und Moderna erneut – Showdown naht
    01.04.22 - Der Aktionär
    Schlussglocke: China‑Werte melden sich zurück, GameStop‑News verpufft – der Tag an der Wall Street
    01.04.22 - Der Aktionär
    Speku­latio­nen um Alnylam – Biotech‑Aktie gibt kräftig Gas
    09.12.21 - PR Newswire
    Direxion Launches mRNA ETF (MSGR)
    Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire
    28.09.21 - PR Newswire
    ONPATTRO® (patisiran) Now Reimbursed in Canada For the Treatment of Hereditary Transthyretin (TTR)-Mediated Amyloidosis (hATTR)
    ONPATTRO® (patisiran) Now Reimbursed in Canada For the Treatment of Hereditary Transthyretin (TTR)-Mediated Amyloidosis (hATTR) Canada NewsWire
    19.07.21 - PR Newswire
    Thinking about trading options or stock in Alnylam Pharmaceuticals, Tesla, Cintas, GameStop, or Microsoft?
    Thinking about trading options or stock in Alnylam Pharmaceuticals, Tesla, Cintas, GameStop, or Microsoft? PR Newswire
    08.12.20 - DGAP
    CENTOGENE und Alnylam Pharmaceuticals schließen Vereinbarung zum Start eines neuen klinischen Programms zur Revolutionierung der Diagnose der Erbkrankheit Transthyretin assoziierte Amyloidose ('ATTRv')
    DGAP-News: Centogene NV / Schlagwort(e): Vereinbarung CENTOGENE und Alnylam Pharmaceuticals schließen Vereinbarung zum Start eines neuen klinischen Programms zur ...

    Newssuche

    Videos

    newspaper
    25.04.24 -34,00%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »